On account of the unique anti-obesity and anti-hyperglycemia dual-function, GLP-1 receptor agonists had great potential to treat CAVD with ability to attenuate ASCVD independent of glucose control (Figure 3). This evidence concerns the gene GLP1R and Obesity.